JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and lowers the price target from $12 to $11.
Ocular Therapeutix (NASDAQ: OCUL) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. This is a 4.35 percent decrease over losses of $(0.23) per share from the same period last year.
Major Wall Street indices closed over 1% higher on Monday ahead of the release of the consumer price index report on Tuesday. The Nasdaq Composite closed 1.48% higher while the S&P 500 ended the session up 1.14%.
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 300 points on Monday.
The Dow traded up 1.01% to 34,211.29 while the NASDAQ rose 1.52% to 11,896.33. The S&P 500 also rose, gaining, 1.07% to 4,134.24.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1.5% on Monday.
The Dow traded up 0.96% to 34,193.83 while the NASDAQ rose 1.52% to 11,896.75. The S&P 500 also rose, gaining, 1.03% to 4,132.54.
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Monday.
Following the market opening Monday, the Dow traded up 0.59% to 34,069.23 while the NASDAQ rose 0.65% to 11,793.71. The S&P 500 also rose, gaining, 0.52% to 4,111.69.